A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Squamous Cell
Chemoradiotherapy
DNA
Female
Fluorouracil
Genetic Therapy
Head and Neck Neoplasms
Humans
Hydroxyurea
Kaplan-Meier Estimate
Male
Maximum Tolerated Dose
Middle Aged
Radiation-Sensitizing Agents
Radiotherapy Planning, Computer-Assisted
Radiotherapy, Intensity-Modulated
Retreatment
Treatment Outcome

authors with profiles

Everett E. Vokes
Mark W. Lingen
Kerstin M. Stenson
Ezra Cohen
Daniel J. Haraf
Ralph R. Weichselbaum
Elizabeth Blair